Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis
Cells · 2025
DOI: 10.3390/cells14171379 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2025. Verfasst von Uri Barash und 5 weiteren Autor:innen. Beteiligte Einrichtung: Technion Integrated Cancer Center (TICC), Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel. Hauptthemen laut MEDLINE: Glucuronidase, Antibodies, Monoclonal, Antibodies, Neutralizing, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Biotherapy Investment, US-Israel binational Science Foundation, Israel Science Foundation.
Abstract (Originalsprache)
Heparanase is the only human enzyme responsible for heparan sulfate (HS) breakdown, an activity that remodels the extracellular matrix (ECM) and strongly drives cancer metastasis and angiogenesis. Compelling evidence implies that heparanase promotes essentially all aspects of the tumorigenic process, namely, tumor initiation, vascularization, growth, metastasis, and chemoresistance. A key mechanism by which heparanase accelerates cancer progression is by enabling the release and bioavailability of HS-bound growth factors, chemokines, and cytokines, residing in the tumor microenvironment and supporting tumor growth and metastasis. The currently available heparanase inhibitors are mostly HS/heparin-like compounds that lack specificity and exert multiple off-target side effects. To date, only four such compounds have progressed to clinical trials, and none have been approved for clinical use. We have generated and characterized an anti-heparanase monoclonal antibody (A54 mAb) that specifically inhibits heparanase enzymatic activity (ECM degradation assay) and cellular uptake. Importantly, A54 mAb attenuates xenograft tumor growth and metastasis (myeloma, glioma, pancreatic, and breast carcinomas) primarily when administered (syngeneic or immunocompromised mice) in combination with conventional anti-cancer drugs. Co-crystallization of the A54 Fab fragment and the heparanase enzyme revealed that the interaction between the two proteins takes place adjacent to the enzyme HS/heparin binding domain II (HBDII; Pro271-Ala276), likely hindering heparanase from interacting with HS substrates via steric occlusion of the active site cleft. Collectively, we have generated and characterized a novel mAb that specifically neutralizes heparanase enzymatic activity and attenuates its pro-tumorigenic effects in preclinical models, paving the way for its clinical examination against cancer, inflammation, and other diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Technion Integrated Cancer Center (TICC), Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel.
- School of Pharmacy, University of Illinois, Chicago, IL 60654, USA.
- The Rosalind Franklin Institute, Harwell OX11 0FA, UK.
- Division of Structural Biology, University of Oxford, Centre for Human Genetics, Oxford OX3 7BN, UK.
ORCID-Profile: Uri Barash, Maali Odeh, Liang Wu
Förderung
- Biotherapy Investment
- US-Israel binational Science Foundation
- Israel Science Foundation
- Israel Cancer Research Fund
- Wellcome Trust
- Medical Research Council (APP14742), UK
- Biotherapy Investments
- EU Marie Sklodowska-Curie Actions (MSCA)
Zitieren
APA
Barash, U., Farhoud, M., Odeh, M., Huberman, E., Wu, L., & Vlodavsky, I. (2025). Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis. Cells. https://doi.org/10.3390/cells14171379
Vancouver
Barash U, Farhoud M, Odeh M, Huberman E, Wu L, Vlodavsky I. Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis. Cells. 2025. doi:10.3390/cells14171379
BibTeX
@article{Barash2025,
author = {Barash, Uri and Farhoud, Malik and Odeh, Maali and Huberman, Eliezer and Wu, Liang and Vlodavsky, Israel},
title = {Heparanase-Neutralizing Monoclonal Antibody (mAb A54) Attenuates Tumor Growth and Metastasis},
journal = {Cells},
year = {2025},
doi = {10.3390/cells14171379}
}
EUVIMED